alexion pharmaceuticals , inc .
notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases ( including facilities and equipment ) as of december 31 , 2007 are: .
9 .
commitments and contingencies legal proceedings on march 16 , 2007 , pdl biopharma , inc. , or pdl , filed a civil action against alexion in the u.s .
district court for the district of delaware .
pdl claims willful infringement by alexion of pdl patents due to sales of soliris .
pdl seeks unspecified damages , but no less than a reasonable royalty , plus attorney 2019s fees .
alexion has denied pdl's claims .
in addition , we filed counterclaims seeking declarations of non-infringement and invalidity of certain u.s .
patents held by pdl .
alexion believes it has good and valid defenses to pdl's claims and intends to vigorously defend the case and pursue its counterclaims .
on february 4 , 2008 , sb2 , inc .
filed a civil action against alexion in the united states district court for the northern district of california .
sb2 , inc .
claims willfull infringement by alexion of sb2 , inc .
patents due to sales of soliris .
sb2 , inc .
seeks unspecified monetary damages , equitable relief and attorneys fees .
alexion believes it has good and valid defenses to sb2's claims and intends to vigorously defend the case and pursue its counterclaims .
the results of such civil actions cannot be predicted with certainty due to their early stages .
however , depending on the outcome of these legal matters , the operating results of the company could be materially impacted through adjustments to cost of sales ( see notes 2 , 6 and 15 for additional information related to royalties ) .
product supply the large-scale product supply agreement dated december 18 , 2002 , or the lonza agreement , between lonza sales ag , or lonza , and us , relating to the manufacture of soliris , was amended in june 2007 .
we amended our supply agreement to provide for additional purchase commitments of soliris of $ 30000 to $ 35000 through 2013 .
such commitments may only be cancelled in limited circumstances. .
